HSFTOOLS Unveils Finder S2: High-Resolution Thermal Imaging in the Palm of Your Hand
BINH DUONG, Vietnam, Feb. 26, 2025 (GLOBE NEWSWIRE) -- HSFTOOLS, an emerging leader in thermal imaging technology, has launched the Finder S2, a high-resolution, smartphone-compatible thermal camera designed for a new era of professional and consumer applications. The release marks a strategic expansion as the company leverages a growing demand for compact, high-performance thermal imaging solutions across various industries.
The global thermal imaging market is on a strong upward trajectory, projected to grow at a CAGR of over 4.2% from 2024 to 2034, driven by HVAC, electrical diagnostics, home safety, and predictive maintenance industries. By aligning its product innovation with these expanding sectors, HSFTOOLS is positioning itself as a key competitor in a space traditionally dominated by larger, legacy brands.
Revolutionizing Thermal Imaging with Portability and Power
The HSFTOOLS Finder S2 distinguishes itself by offering a professional-level thermal imaging solution in a remarkably small package. Unlike traditional handheld thermal cameras, the Finder S2 is a battery-free device powered directly by your phone, ensuring it's always ready for use without the need for charging. Its compact size allows it to fit into tight spaces where larger cameras can't maneuver. This combination of portability and power is set to redefine how thermal imaging is used in both professional and personal settings.
' Our goal with the Finder series was to break down the barriers to thermal imaging, making it accessible to everyone,' says Jule Yue, marketing director for HSFTOOLS. " The Finder S2 is a testament to that vision, offering unparalleled resolution and accuracy in a device that fits in your pocket.'
The Finder S2 boasts a thermal resolution of 256x192, a significant leap from its predecessor, the Finder S1. While this may seem modest compared to megapixel digital cameras, it's a notable achievement in thermal imaging technology.
To further enhance image quality, HSFTOOLS employs its 'Super Resolution' enhancement algorithm, which upscales images to 960x720, delivering sharp, detailed visuals. This technology ensures that users can accurately identify and analyze temperature variations with ease.
The Technical Edge: How Finder S2 Stands Out
At the heart of the Finder S2 's capabilities lies its advanced thermal sensor, which delivers exceptional sensitivity and accuracy. With a NETD thermal sensitivity of 40 mK, the Finder S2 can detect minute temperature differences, making it suitable for a wide range of applications, from detecting energy inefficiencies in homes to diagnosing electrical faults. .
The device's sensitivity allows users to pinpoint even subtle temperature inconsistencies, ensuring accurate diagnoses and efficient problem-solving. The device's temperature range spans from -4°F to 752°F (-20°C to 400°C), accommodating diverse thermal measurement needs.
The HSFTOOLS app, which serves as the user interface for the Finder S2, offers a comprehensive suite of features designed to enhance the imaging experience. Users can easily capture photos and videos, customize temperature displays, and measure temperatures at specific points or areas within the image.
The app also allows for the adjustment of emissivity settings to ensure accurate temperature readings on various surfaces. With 15 preset color palettes and the option to create custom palettes, users can tailor the visualization to their specific needs. This level of customization ensures that users can optimize the thermal imaging experience for their specific applications.
'We've put a lot of effort into making the Finder S2 not only powerful but also incredibly user-friendly,' explains Yue. 'The app is designed to be intuitive, providing users with the tools they need to get the most out of their thermal imaging experience.'
The Tiny but Mighty Tool for All Industries
The Finder S2 's design also reflects a commitment to durability and practicality. While compact and lightweight, it's built to withstand the rigors of daily use. Its compatibility with Android devices ensures broad accessibility, making it a versatile tool for professionals and DIYers alike. However, some users may find the reliance on a smartphone for power and processing to be a limitation, especially in situations where battery life is a concern. The device's battery-free operation, powered directly by the connected phone, eliminates the need for external power sources, enhancing its portability and convenience.
The device's lightweight design, weighing only 0.92 ounces (26 grams), and extended operational capability of 6-8 hours on smartphones and tablets, further enhance its appeal for extended field use. The inclusion of a storage bag, USB-C extension adapter, and comprehensive warranties—1 year for the device and 10 years for the sensor—along with lifetime firmware updates and technical support, underscore HSFTOOLS' commitment to quality and customer satisfaction.
What does this entail? It means enhanced mobility for security and surveillance, improved efficiency in industrial inspections, increased field accessibility for outdoor and remote operations, and cost-effective solutions for small businesses.
A Vision for Smarter Thermal Imaging
The thermal imaging camera market is experiencing significant growth, with projections indicating a rise from approximately $3.91 billion in 2024 to around $7.70 billion by 2034, reflecting a compound annual growth rate (CAGR) of 7.8% during this period. This expansion is driven by advancements in infrared technology and increasing demand across sectors such as security, surveillance, industrial applications, and healthcare.
HSFTOOLS' Finder S2 enters this expanding market with features designed to meet both professional and consumer needs. The company sees a future where thermal technology is as standard as digital cameras in inspection work, with integration into smart home applications, IoT (Internet of Things) devices, and AI-powered diagnostics.
With Finder S2 now available, HSFTOOLS is accelerating its market penetration strategy, focusing on business growth, industry partnerships, and ongoing R&D (research and development). As demand for smart, accessible thermal imaging solutions increases, the company is set to challenge industry norms and drive innovation in a swiftly growing market.
Company: HSFTOOLS
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
31 minutes ago
- Yahoo
Body Armor Plates Market is Forecasted to Reach US$1225 Million in 2031, Says Stratview Research
Detroit, Aug. 11, 2025 (GLOBE NEWSWIRE) -- The global body armor plates market size was valued at US$962.4 million in 2024 and is projected to reach US$1225 million by 2031, witnessing a market growth CAGR of 3.5% from 2024 to 2031, according to an analysis by Stratview Research. Stratview Research, a global market research firm, has launched a report on the global body armor plates market, which provides a comprehensive outlook of the global and regional industry forecast, current & emerging market trends, segment analysis, competitive landscape, & more. Click here to get a free sample of the report: Market Statistics Market Size in 2024 US$962.4 million Market Size in 2031 US$1225 million Growth (CAGR) 3.5% during 2024-2031 Cumulative Sales Opportunity 2024 to 2031 US$8.78 billion Leading Product Type ICW Armor Plates Leading Level of Protection Type Level IV + Level IIIA/Level II Leading Material Type Ceramic Leading End-User Type Military Leading Region North America Forecast Period 2024-2031 Trend Period 2019-2022 Base Year 2023 Number of Segments Covered 5 Number of Tables & Graphs 100+ Country-Level Market Assessment 20 Segment Insights & Market Share Analysis of the Body Armor Plates Market: The global body armor plates market is segmented based on product type, level of protection type, material type, end-user type, and region. Based on product type – The body armor plates market is classified based on product type: stand-alone armor plates and ICW armor plates. ICW (In-Conjunction-With) armor plates are anticipated to emerge as the leading product category, demonstrating the most rapid growth throughout the forecast period. ICW plates are meant to be used in conjunction with soft armor components, like Kevlar or other ballistic fabrics, placed inside a carrier or vest. The combination creates a multi-hit protective system that increases protection against a range of threats, including bullets and other projectiles. By combining the merits of hard and soft armor, ICW plates provide the perfect balance of flexibility, comfort, and protection. The soft armor layer absorbs and disperses the impact energy, and the hard plate provides much-needed resistance against penetration. Based on level of protection type – The body armor plates market is classified based on protection levels such as Level IIIA, Level IIIA + SP/KR/SP-KR, Level III, Level IV, Level III + Level IIIA/Level II, and Level IV + Level IIIA/Level II. Amongst these, Level IV + Level IIIA/Level II plates are expected to dominate the market throughout the forecast period. Level IV + Level IIIA/Level II body armor provides the utmost protection that is presently available, strong enough to hold against steel-core AP rifle ammo and several hits with high-speed ammunition. Such provides it an imperative element as part of the frontline military team, special force operators, and tactical law enforcers fighting in high-threat situations. A greater number of combat operations, urban warfare scenarios, and active shooters have caused higher demand for optimum ballistic protection, which results in the use of Level IV plates. Besides their strong performance, contemporary Level IV plates are now also becoming lighter and more ergonomic as a result of advances in material science, including the employment of ceramic composites and ultra-high-molecular-weight polyethylene. These innovations improve wearer mobility without compromising on safety, thus making them all the more desirable to defense agencies and law enforcement organizations globally. Based on material type – The body armor plates market is classified based on material type into ceramic, ultra-high-molecular-weight polyethylene (UHMWPE), aramid, and other materials. Ceramic is expected to remain the dominant material in the body armor plates market. Of these, ceramic is still a choice of body armor plate makers based on its promising balance of performance, weight, and price. Ceramic plates are lighter and cheaper than UHMWPE, but stronger and lighter than their steel counterparts. Such properties of ceramics make ceramic material perfectly suitable for reaching high levels of ballistic protection with negligible compromise in mobility or comfort. Consequently, ceramic will continue to be the leading material type in the body armor plates market during the forecast period. Based on end-user type – The body armor plates market is classified based on end-user type, such as military, homeland security, and commercial. The military category accounted for the largest market share and is also likely to witness the fastest growth during the forecast period. This is led mainly by the excessive need for sophisticated ballistic protection for military operations such as border battles, peacekeeping, and counter-terrorism missions. Body armor plates are a critical tool for protecting soldiers from armor-piercing rounds and other high-impact dangers, and they are rolled out in large quantities across entire military units. Widespread adoption of these plates, combined with consistent modernization and defense procurement initiatives, maintains strong demand within the military market. To know the most attractive segments, click here for a free sample of the report: Which Region Shows the Most Promising Growth Forecast and Opportunity? The analysis suggests that North America is expected to be the dominant region, while Asia-Pacific (APAC) is expected to be the fastest-growing region. This growth outlook is mainly attributed to the following: This is mainly because of heavy investments by the U.S. Department of Defense (DoD) and the Department of Homeland Security (DHS) in providing military personnel and homeland security forces with high-tech protective equipment. The location of major industry participants like Point Blank Enterprises, Inc., HESCO, Hardwire LLC, and Armor Express—most of whom are DoD and DHS major suppliers—further confirms the region's solid market position. Conversely, the Asia-Pacific market is expected to be the most rapidly growing market during the next five years. This expansion is being driven by increasing defense budgets in nations such as China and India, due to rising security concerns and continuous geopolitical tensions. The presence of leading regional producers, including Beijing Tongyizhong New Material Technology Corporation and MKU LIMITED, is also adding to the region's increasing competitiveness and attractiveness. These drivers are anticipated to generate huge market opportunities and push the growth of body armor plates throughout the region. Body Armor Plates Market Drivers: Some of the key drivers listed in the report are given below. Increasing global security threats. Rising defense expenditures and growing demand for advanced personal protection among military and law enforcement agencies. Technological advancements in lightweight ballistic materials. Modernization programs and heightened geopolitical tensions. Competitive Landscape: Top 10 Companies in the Body Armor Plates Market: The market is fragmented, with over 50 players. Most of the major players compete in some of the governing factors, including price, service offerings, regional presence, etc. Stratview Research has identified the following companies as the top market players: Point Blank Enterprises, Inc. Cadre Holdings Craig International Ballistics Pty. Ltd Xtek US Armor Corporation Mars Armor TYR Tactical Beijing Tongyizhong New Material Technology Corporation Hardware LLC Hesco. What Deliverables Will You Get in This Report? Key questions this report answers Relevant content in the report How big is the sales opportunity? In-depth analysis of the Body Armor Plates Market How lucrative is the future? Market forecast and trend data and emerging trends Which regions offer the best sales opportunities? Global, regional, and country-level historical data and forecasts Which are the most attractive market segments? Market segment analysis and forecast Who are the top players and their market positioning? Competitive landscape analysis, Market share analysis How complex is the business environment? Porter's five forces analysis, PEST analysis, Life cycle analysis What are the factors affecting the market? Drivers & challenges Will I get the information on my specific requirements? 10% free customization For Customization or Any Other Queries, Get in Touch with Our Industry Experts at - sales@ Related Reports: Body Armor Market Soft Body Armor Market Also Read Our Newly Published Reports on GlobeNewswire: Military GNSS Receiver Market Military GPS Receiver Market About us – Stratview Research is a global market research and consulting firm that highly specializes in IT & Telecom, aerospace & defense, chemicals, and a few other industries. It launches a limited number of reports annually on the above-mentioned specializations. Thorough analysis and accurate forecasts in this report enable the readers to take convincing business decisions. Stratview Research has been helping companies meet their global and regional growth objectives by offering customized research services. These include market assessment, due diligence, opportunity screening, voice of customer analysis, market entry strategies, and more. Are you looking for any specific data customized to your objectives? We are just a mail away. CONTACT: Stratview Research Visit : Mail Us : sales@ Call Us : +1-313-307-4176Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
IO Biotech Announces Clinical Improvement in Progression Free Survival Demonstrated in Pivotal Phase 3 Trial of Cylembio® plus KEYTRUDA® (Pembrolizumab) for the Treatment of First-line Advanced Melanoma, but Statistical Significance Narrowly Missed
Patients treated with Cylembio (imsapepimut and etimupepimut, adjuvanted) plus pembrolizumab achieved improvement in progression free survival (PFS) compared to patients treated with pembrolizumab monotherapy, HR=0.77 (CI 0.58-1.00), (p=0.056), with median PFS (mPFS) of 19.4 months vs. 11.0 months, respectively; the results on the primary endpoint narrowly missed the study's statistical significance threshold of p≤0.045 In patients enrolled in this study without prior neo-adjuvant/adjuvant anti-PD-1 treatment (n=371), patients treated with Cylembio plus pembrolizumab achieved improvement in PFS, HR: 0.74 (CI 0.56-0.98) (nominal p=0.037), with mPFS of 24.8 months vs. 11.0 months for the control arm Improvement in PFS was achieved across virtually all subgroups, including those with poor prognostic factors A profound effect was observed in patients with PD-L1 negative tumors treated with Cylembio plus pembrolizumab, HR: 0.54 (CI 0.35-0.85) (nominal p=0.006), with mPFS of 16.6 months vs. 3.0 months for the control arm A trend towards improvement in overall survival (OS) was observed in patients treated with Cylembio plus pembrolizumab (OS not yet mature), HR=0.79 (CI 0.57-1.10) Cylembio plus pembrolizumab was well tolerated, with no new safety signals observed IO Biotech plans to meet with the FDA this fall to discuss the data and next steps for a potential regulatory submission Company to host conference call today at 8:30 a.m. ET to discuss these results NEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT) today announces topline results from the pivotal Phase 3 trial of its investigational, immune-modulatory, off-the-shelf therapeutic cancer vaccine, Cylembio® (imsapepimut and etimupepimut, adjuvanted). The trial evaluated Cylembio in combination with Merck's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), vs. pembrolizumab alone as a first-line treatment in 407 patients with unresectable or metastatic (advanced) melanoma. In the study, Cylembio plus pembrolizumab demonstrated clinical improvement in progression free survival compared to pembrolizumab alone, but statistical significance was narrowly missed on the primary endpoint. 'In this study, we observed a highly encouraging improvement in progression free survival and consistent trend in overall survival in patients treated with Cylembio,' said Mai-Britt Zocca, PhD, president and chief executive officer of IO Biotech. 'The magnitude and durability of clinical effect observed consistently across subgroups supports our confidence in Cylembio and its potential as a treatment for advanced melanoma patients. We look forward to engaging with the FDA to determine a potential path to approval based on these data.' The randomized, open-label study enrolled 407 patients across more than 100 sites worldwide. Patients received either Cylembio in combination with pembrolizumab (n=203) or pembrolizumab alone (n=204). The primary endpoint was PFS as assessed by a blinded independent review committee per RECIST v1.1. The early and sustained separation of PFS curves demonstrated an improvement with a hazard ratio of 0.77 [95% CI: 0.58-1.00; p=0.056; threshold for significance p≤0.045]. Based on an intent-to-treat analysis, patients in the study treated with Cylembio in combination with pembrolizumab achieved 19.4 months of median progression free survival compared to 11.0 months in patients treated with pembrolizumab alone. Although not yet mature, a trend toward an improvement in overall survival was also observed [HR 0.79 (95% CI: 0.57-1.10)]; the company expects OS to mature over the next six to nine months. Improvement in PFS was achieved across virtually all subgroups, including those with poor prognostic factors, with a profound effect in patients with PD-L1 negative tumors treated with Cylembio plus pembrolizumab (n=67) compared to patients treated with pembrolizumab monotherapy (n=63), HR: 0.54 (CI 0.35-0.85) (nominal p=0.006), with mPFS of 16.6 months vs. 3.0 months, respectively. Additionally, in a post hoc analysis of patients enrolled in this study without prior anti-PD-1 treatment (n=371), patients treated with Cylembio plus pembrolizumab achieved improvement in PFS compared to patients treated with pembrolizumab monotherapy, HR: 0.74 (CI 0.56-0.98) (nominal p=0.037), with mPFS of 24.8 months vs. 11.0 months, respectively. The combination was well tolerated, with no new safety signals observed. Injection site reactions, which were transient and resolved on treatment, were the most commonly reported adverse events in the combination arm, with 56% of patients receiving Cylembio plus pembrolizumab reporting an event. 'In this study, patients treated with Cylembio in combination with pembrolizumab have achieved the longest median PFS ever observed in a Phase 3 clinical study in advanced melanoma, and in the PD-L1 negative population, patients achieved a remarkable 16.6 months of median PFS, compared to 3.0 months in patients treated with pembrolizumab alone,' said Omid Hamid, MD, Director, Clinical Research and Immunotherapy at The Angeles Clinic and Research Institute, A Cedars Sinai Affiliate. 'The significant benefit seen across patients with poor prognostic factors, including PD-L1 negative patients, cannot be overlooked. Given the notable safety profile and the strong clinical effect observed with Cylembio, as well as the unmet need in advanced melanoma patients, Cylembio, if approved, has the potential to become a new standard of care for patients with advanced melanoma.' 'These data show the potential of a therapeutic cancer vaccine in patients with metastatic melanoma,' said Jessica Hassel, MD, Professor at the Department of Dermatology and National Center for Tumor Diseases at the University Hospital Heidelberg, Germany, and lead enrolling investigator for the Phase 3 trial. 'We were thrilled to play such an important part in this study and to have had the ability to offer our patients an investigational therapy that potentially offers improvements in PFS while not adding significant systemic toxicity.' 'Delaying progression and improving survival is the ultimate treatment goal for patients and although overall survival is not yet mature, the trend we are seeing in OS with separation of the curves is encouraging, with a consistent PFS clinical improvement and OS trend favoring the combination arm across virtually all subgroups, with no new safety signals or significant additional systemic toxicity,' said Qasim Ahmad, MD, chief medical officer of IO Biotech. 'We are deeply grateful to the patients for their participation in this study, as well as to investigators and study coordinators whose dedication and collaboration brings us one step closer to delivering a new treatment option to patients in need.' 'Since reporting the positive outcome of our Phase 1/2 study (MM1636) in a similar patient population, we have been eagerly awaiting these results supporting the activity of Cylembio combined with an anti-PD-1 in patients with advanced melanoma,' said Inge Marie Svane, MD, PhD, Professor, Director of the National Center for Cancer Immune Therapy (CCIT) at the Copenhagen University Hospital, Herlev and Principal Investigator in the Phase 3 trial. 'These data provide evidence that a therapeutic cancer vaccine can improve progression free survival in patients with metastatic disease.' Based on these results, IO Biotech plans to meet with the United States (US) Food and Drug Administration (FDA) this fall to discuss the totality of data and determine next steps for submission of a Biologics License Application (BLA) for the treatment of advanced melanoma. Additionally, the company plans to present more detailed results from the IOB-013 study at an upcoming medical meeting. Conference Call and Webcast Information IO Biotech management will hold a conference call and webcast today at 8:30 a.m. ET to discuss these clinical data results. Participants can register for the live webcast here. The live webcast and replay will be available through IO Biotech's website here. About the IOB-013/KN-D18 Pivotal Phase 3 Clinical Trial IOB-013/KN-D18 ( NCT05155254) was an open label, randomized Phase 3 pivotal clinical trial evaluating Cylembio® in combination with Merck's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) versus pembrolizumab alone in patients with previously untreated, unresectable or metastatic (advanced) melanoma. Enrollment in the trial was completed by December 2023 with a total of 407 patients enrolled from more than 100 centers across the United States, Europe, Australia, Turkey, Israel and South Africa. The primary endpoint of the study was progression free survival. Secondary endpoints include overall response rate, overall survival, durable objective response rate, complete response rate, duration of response, time to complete response, disease control rate, and incidence of adverse events and serious adverse events (safety and tolerability). Biomarkers in the blood and tumor tissue will also be assessed as exploratory endpoints. The company reported topline results from this trial in the third quarter of 2025. IO Biotech is sponsoring the Phase 3 trial and Merck is supplying pembrolizumab. About Cylembio® Cylembio® (imsapepimut and etimupepimut, adjuvanted) is an investigational, immune-modulatory, off-the-shelf therapeutic cancer vaccine candidate designed to kill both tumor cells and immune-suppressive cells in the tumor microenvironment (TME) by stimulating activation and expansion of T cells against indoleamine 2,3-dioxygenase 1 (IDO1) positive and/or programmed death-ligand 1 (PD-L1) positive cells. The company is currently conducting a pivotal Phase 3 trial (IOB-013/KN-D18; NCT05155254) investigating Cylembio in combination with Merck's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) versus pembrolizumab alone in patients with advanced melanoma, a Phase 2 basket trial (IOB-022/KN-D38; NCT05077709) investigating Cylembio in combination with pembrolizumab as first line treatment in patients with advanced solid tumors, and a Phase 2 basket trial (IOB-032/PN-E40; NCT05280314) investigating Cylembio in combination with pembrolizumab as neo-adjuvant/adjuvant treatment of patients with solid tumors. Enrollment in the Phase 3 trial was completed rapidly by December 2023 with topline results from this trial reported in the third quarter of 2025. Enrollment in the two ongoing company-sponsored Phase 2 clinical trials is now complete. The clinical trials are sponsored by IO Biotech and conducted in collaboration with Merck, which is supplying pembrolizumab. IO Biotech maintains global commercial rights to Cylembio. Cylembio® is a registered trademark of IO Biotech ApS, a subsidiary of IO Biotech. KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA (known as MSD outside of the US and Canada). About IO Biotech IO Biotech is a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines based on its T-win® platform. The T-win platform is based on a novel approach to cancer vaccines designed to activate T cells to target both tumor cells and the immune-suppressive cells in the tumor microenvironment. IO Biotech is advancing its lead cancer vaccine candidate, Cylembio®, in clinical trials, and additional pipeline candidates through preclinical development. IO Biotech is headquartered in Copenhagen, Denmark and has US headquarters in New York, New York. For further information, please visit Follow us on our social media channels on LinkedIn and X (@IOBiotech). Forward-Looking Statement This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including statements regarding the timing or outcome of communications with the FDA, submission of a BLA, the launch of Cylembio, and statements regarding other current or future clinical trials, their progress, enrollment or results, or the company's financial position or cash runway, are based on IO Biotech's current assumptions and expectations of future events and trends, which affect or may affect its business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of the date hereof and should not be unduly relied upon. Except to the extent required by law, IO Biotech undertakes no obligation to update these statements, whether as a result of any new information, future developments or otherwise. Contacts: InvestorsMaryann Cimino, Director of Investor RelationsIO Biotech, Inc.617-710-7305mci@ MediaJulie beim Abrufen der Daten Melden Sie sich an, um Ihr Portfolio aufzurufen. Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten
Yahoo
2 hours ago
- Yahoo
ESET Research: Russian RomCom group exploits new vulnerability, targets companies in Europe and Canada
If you use WinRAR or other affected components such as the Windows versions of its command line utilities, or the portable UnRAR source code, upgrade immediately to the latest version. ESET researchers have discovered a previously unknown zero-day vulnerability in WinRAR being exploited in the wild by Russia-aligned group RomCom. Analysis of the exploit led to the discovery of the vulnerability, now assigned CVE-2025-8088: a path traversal vulnerability, made possible with the use of alternate data streams. After notification, WinRAR released a patched version on July 30th, 2025. Successful exploitation attempts delivered various backdoors used by the RomCom group, specifically a SnipBot variant, RustyClaw, and the Mythic agent. This campaign targeted financial, manufacturing, defense, and logistics companies in Europe and Canada. BRATISLAVA, Slovakia, Aug. 11, 2025 (GLOBE NEWSWIRE) -- ESET researchers have discovered a previously unknown vulnerability in WinRAR, exploited in the wild by Russia-aligned group RomCom. According to ESET telemetry, malicious archives were used in spearphishing campaigns between July 18 to July 21, 2025, targeting financial, manufacturing, defense, and logistics companies in Europe and Canada. The aim of the attacks was cyberespionage. This is at least the third time that RomCom has been caught exploiting a significant zero-day vulnerability in the wild. 'On July 18, we observed a malicious DLL named in a RAR archive containing unusual paths that caught our attention. Upon further analysis, we found that the attackers were exploiting a previously unknown vulnerability affecting WinRAR, including the then-current version 7.12. On July 24, we contacted the developer of WinRAR; the same day the vulnerability was fixed in beta version with a full version released few days later. We advise WinRAR users to install the latest version as soon as possible to mitigate the risk,' says ESET researcher Peter Strýček who made the discovery along with another ESET researcher Anton Cherepanov. The vulnerability, CVE-2025-8088, is a path traversal vulnerability, which is made possible via the use of alternate data streams. Disguised as an application document, the weaponized archives exploited a path traversal flow to compromise its targets. In the spearphishing email, the attackers sent a CV hoping that a curious target would open it. According to ESET telemetry, none of the targets were compromised. The attackers, however, had conducted reconnaissance beforehand and the emails were highly targeted. Successful exploitation attempts delivered various backdoors used by RomCom group – specifically, a SnipBot variant, RustyClaw, and the Mythic agent. ESET Research attributes the observed activities to RomCom with high confidence based on the targeted region, tactics, techniques, and procedures (TTPs), and the malware used. RomCom (also known as Storm-0978, Tropical Scorpius, or UNC2596) is a Russia-aligned group that conducts both opportunistic campaigns against selected business verticals and targeted espionage operations. The group's focus has shifted to include espionage operations collecting intelligence, in parallel with its more conventional cybercrime operations. The backdoor used by the group is capable of executing commands and downloading additional modules to the victim's machine. It is not the first time that RomCom has used exploits to compromise its victims. In 2023-06, the group performed a spearphishing campaign targeting defense and governmental entities in Europe, with lures related to the Ukrainian World Congress. 'By exploiting a previously unknown zero-day vulnerability in WinRAR, the RomCom group has shown that it is willing to invest serious effort and resources into its cyberoperations. The discovered campaign targeted sectors that align with the typical interests of Russian-aligned APT groups, suggesting a geopolitical motivation behind the operation,' concludes Strýček. For a more detailed analysis and technical breakdown of RomCom's latest campaign, check out the latest ESET Research blogpost 'Update WinRAR tools now: RomCom and others exploiting zero-day vulnerability' on Make sure to follow ESET Research on Twitter (today known as X), BlueSky, and Mastodon for the latest news from ESET Research. About ESET ESET® provides cutting-edge cybersecurity to prevent attacks before they happen. By combining the power of AI and human expertise, ESET stays ahead of emerging global cyberthreats, both known and unknown—securing businesses, critical infrastructure, and individuals. Whether it's endpoint, cloud, or mobile protection, our AI-native, cloud-first solutions and services remain highly effective and easy to use. ESET technology includes robust detection and response, ultra-secure encryption, and multifactor authentication. With 24/7 real-time defense and strong local support, we keep users safe and businesses running without interruption. The ever-evolving digital landscape demands a progressive approach to security: ESET is committed to world-class research and powerful threat intelligence, backed by R&D centers and a strong global partner network. For more information, visit or follow our social media, podcasts, and blogs. CONTACT: Media contact: Jessica Beffa 720-413-4938Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
